Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Type
(
1 selected
)
Type
Guidance (40)
Guidance programme
(
1 selected
)
Guidance programme
NICE guidelines (1)
Technology appraisal guidance (40)
Apply filters
Showing 1 to 40 of 40
Sort by
Title
Date
Apply sorting
lung cancer
Remove lung cancer filter
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Alectinib for adjuvant treatment of ALK-positive non-small-cell
lung cancer
[ID6368]
Technology appraisal guidance
11 December 2024
Atezolizumab for untreated advanced or recurrent non-small cell
lung cancer
when platinum-doublet chemotherapy is unsuitable [ID6218]
Technology appraisal guidance
TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell
lung cancer
after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]
Technology appraisal guidance
TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell
lung cancer
[ID4000]
Technology appraisal guidance
TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell
lung cancer
[ID1261]
Technology appraisal guidance
TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell
lung cancer
[ID5114]
Technology appraisal guidance
TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell
lung cancer
[ID3949]
Technology appraisal guidance
TBC
Cimavax for treating wild-type EGFR-positive non-small-cell
lung cancer
[1259]
Technology appraisal guidance
TBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell
lung cancer
after anti-PD-L1 treatment and chemotherapy [ID6398]
Technology appraisal guidance
TBC
Crizotinib for treating ROS1-positive advanced non-small-cell
lung cancer
(MA review of TA529) [ID6289]
Technology appraisal guidance
16 October 2024
Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell
lung cancer
[ID6220]
Technology appraisal guidance
TBC
Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell
lung cancer
[ID3906]
Technology appraisal guidance
TBC
Lung cancer
(non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]
Technology appraisal guidance
TBC
Lung cancer
(non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
Technology appraisal guidance
TBC
Lurbinectedin for treating advanced small-cell
lung cancer
on or after platinum-based chemotherapy [ID3872]
Technology appraisal guidance
TBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell
lung cancer
[ID6310]
Technology appraisal guidance
TBC
Nivolumab for adjuvant treatment of resected non-small-cell
lung cancer
[ID4053]
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell
lung cancer
[ID6248]
Technology appraisal guidance
TBC
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell
lung cancer
after complete tumour resection (Review of TA761) [ID5120]
Technology appraisal guidance
14 August 2024
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell
lung cancer
[ID6328]
Technology appraisal guidance
TBC
Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell
lung cancer
[ID5094]
Technology appraisal guidance
16 October 2024
Pembrolizumab for adjuvant treatment of resected non-small-cell
lung cancer
[ID3907]
Technology appraisal guidance
16 October 2024
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell
lung cancer
[ID3861]
Technology appraisal guidance
TBC
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell
lung cancer
after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]
Technology appraisal guidance
TBC
Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell
lung cancer
[ID4006]
Technology appraisal guidance
TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell
lung cancer
after pembrolizumab with platinum-based chemotherapy [ID4028]
Technology appraisal guidance
TBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell
lung cancer
[ID3873]
Technology appraisal guidance
TBC
Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell
lung cancer
[ID3985]
Technology appraisal guidance
TBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell
lung cancer
[ID6361]
Technology appraisal guidance
TBC
Sacituzumab govitecan for treating advanced non-small-cell
lung cancer
after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]
Technology appraisal guidance
TBC
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell
lung cancer
(MA review of TA760) [ID6293]
Technology appraisal guidance
13 November 2024
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell
lung cancer
(MA review of TA781) [ID6287]
Technology appraisal guidance
26 February 2025
Sugemalimab with chemotherapy for untreated metastatic non-small-cell
lung cancer
[ID4001]
Technology appraisal guidance
TBC
Tarlatamab for previously treated advanced small-cell
lung cancer
[ID6364]
Technology appraisal guidance
11 December 2024
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell
lung cancer
after 1 or more systemic treatments [ID6253]
Technology appraisal guidance
TBC
Tislelizumab for treating advanced non-small-cell
lung cancer
after platinum-based chemotherapy [ID6161]
Technology appraisal guidance
TBC
Tislelizumab in combination for untreated advanced non-small-cell
lung cancer
[ID6162]
Technology appraisal guidance
TBC
Treatments for non-small-cell
lung cancer
[ID6234]
Technology appraisal guidance
TBC
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell
lung cancer
[ID4061]
Technology appraisal guidance
TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell
lung cancer
[ID1277]
Technology appraisal guidance
TBC
Current page
1
Page
1
of
1
Results per page
10
25
50
All
Back to top